Tales From the Road2019-03-15T10:17:33-04:00

Tales From The Road

This panel brings together biotech and medtech entrepreneurs to tell their stories of raising capital. You’ll hear their firsthand accounts of navigating the fundraising process and raising capital. Topics may include:

• What stumbling blocks had they hit?
• How had they solved the issues, and what had they learned about raising capital?
• How did they go about finding potential investors, and how did they determine which investors they should pursue?

The panel discusses what the early stage fundraising process was like for them and how others can build an outbound marketing campaign to raise money.

Moderator

• Greg Mannix, VP of International Business Development, Life Science Nation
Greg Mannix is Vice President of International Business Development at Life Science Nation. After graduating from the University of California, he moved to Europe where he began a career in the life sciences and obtained a Master’s degree from IE Business School in Madrid. He has extensive experience in sales and marketing management in the medical devices field. He has worked extensively in Europe, North America and Latin America and he speaks English, Spanish and French. Greg’s role at LSN is to provide international early-stage companies with the tools and strategies to succesfully fundraise and to facilitate cross-boarder investments, licensing and M&A transactions.

Panelists

• Ashley Nagle, CEO, Seagull Therapeutics
Ashley Nagle is the CEO of SeaGull Therapeutics, a preclinical stage company treating cancer by reprogramming the tumour microenvironment. In addition, he is the Strategy and Business Director at Domain Therapeutics, a biotech company that creates spin-off entities to develop each of its pre-clinical programmes. From his time in Lonza Biologics, Almac Sciences and Fulcrum Pharma, Ashley has experience in development of both large and small molecules, experience applied in the early stage companies with whom he has worked over the past 10 years. Ashley has a BSc and MSc in chemistry and an MBA.

• William Kohlbrenner, CEO, NeuroLucent
Dr. Kohlbrenner is CEO of NeuroLucent, a Chicago-based company working on Alzheimer’s disease. In addition, Bill is currently Chief Scientific Officer at Life Science Nation (LSN) and is Consulting Scientist for Boston Innovation Capital. Prior to NeuroLucent, Bill was a director at AbbVie, where he led a global scouting team and conducted strategic assessments of early- and late-stage pipeline opportunities. Earlier in his career, Bill led drug discovery research programs in oncology, antivirals, and antibacterials. Bill has co-authored numerous research articles (~60) examining the fundamental aspects of various drug targets and the molecular basis of drug action. He received his Ph.D. from the State University of New York (SUNY) and completed postdoctoral training at the Molecular Biology Institute at UCLA.

• Robert Lauritzen, CEO & Co-Founder, Cerebriu A/S
Robert Lauritzen, CEO and Co-Founder of medical imaging software solutions company Cerebriu is a leader, intra- and entrepreneur with more than 25 years’ of experience in the intersection between life science and IT. Prior to Cerebriu, Robert co-founded DentalMan, a portable dental unit medical device start-up, he partnered at IT software development and management consulting companies, managed IT applications within Ferring Pharmaceuticals, and the past decade as VP life science application outsourcing at publicly listed NNIT.

• Walter Schmidt , CEO, Accanis Biotech F&E GmbH & CoKG
ACCANIS is actively pursuing partnerships to support its first-in-class therapeutics at all development stages.
Professional background: Walter Schmidt, PhD (CEO and founder) is a serial biotech entrepreneur and business angel with over 2 decades experience in the industry. A biologist by training, he has co-founded several biotech companies in Vienna including AFFiRiS, a therapeutic vaccine company with an advanced clinical program, as well as InterCell AG (now Valneva Austria GmbH), the first biotech company listed on the Austrian stock exchange.

Go Back to Agenda